Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381395 | 1.00 | MCL1 (0.37) | MCL1AKR1C3AKR1C2NOS3NOS1 | |
| SCHEMBL3788111 | 0.83 | MCL1 (0.37) | MCL1AKR1C3AKR1C2NOS3NOS1 | |
| SCHEMBL19082496 | 0.80 | KMT2A (0.45) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL14537914 | 0.78 | MCL1 (0.46) | MCL1AKR1C3AKR1C2NOS3NOS1 | |
| SCHEMBL389284 | 0.78 | MAPT (0.38) | MCL1AKR1C3AKR1C2NOS3NOS1 | |
| SCHEMBL5047332 | 0.77 | MCL1 (0.36) | MCL1AKR1C3AKR1C2NOS3NOS1 | |
| SCHEMBL31379107 | 0.77 | HSD17B10 (0.38) | MCL1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1359056 | 0.77 | MEN1 (0.37) | MEN1KMT2ALMNAMAPT | |
| SCHEMBL22411226 | 0.77 | HPGD (0.42) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL3791261 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TSHRLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-02-04 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | CRY1, CRY2, CCNT1 | MCL1 1139/4885AKR1C3 1949/4885AKR1C2 2356/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MCL1 3100/4885AKR1C3 1322/4885AKR1C2 1623/4885 |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | MCL1 1139/4885AKR1C3 1949/4885AKR1C2 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.